Phuturdex › Drugs › Erythromycin
Drugs in development · updated 13 November 2026
Erythromycin: clinical trials and development status
Other names and codes: Erygel, Erycette, Eryc Sprinkles, Akne-Mycin
As of 13 November 2026 Erythromycin is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 12 diseases. The most advanced phase is III.
Authorisation
- EU not available
- Italy not available
- Germany not available
- US yes (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
US-listed companies sponsoring active trials: Genmab (Nasdaq: GMAB, 1 trial). Data from official sources, not financial advice.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
What it is
A broad-spectrum, macrolide antibiotic with antibacterial activity. Erythromycin diffuses through the bacterial cell membrane and reversibly binds to the 50S subunit of the bacterial ribosome. This prevents bacterial protein synthesis. Erythromycin may be bacteriostatic or bactericidal in action, depending on the concentration of the drug at the site of infection and the susceptibility of the organism involved.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Premature rupture of membranes | III | 1 | NCT06273891 |
| Preterm premature rupture of the membranes | III | 1 | NCT06273891 |
| Acute myeloid leukemia | II | 1 | NCT06858618 |
| Breast neoplasm | I–II | 1 | NCT05579366 |
| Endometrial neoplasm | I–II | 1 | NCT05579366 |
| Fallopian tube neoplasm | I–II | 1 | NCT05579366 |
| Mesothelioma | I–II | 1 | NCT05579366 |
| Non-small-cell lung carcinoma | I–II | 1 | NCT05579366 |
| Ovarian neoplasm | I–II | 1 | NCT05579366 |
| Triple-negative breast neoplasm | I–II | 1 | NCT05579366 |
| Uterine cervix neoplasm | I–II | 1 | NCT05579366 |
| Uterine neoplasm | I–II | 1 | NCT05579366 |
Everything on Erythromycin
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 13 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.